◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

FDC Limited (FDC) Financial History

Name: FDC Limited (FDC) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

FDC Limited (FDC) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 7,076 employees. Its market capitalization is roughly ₹57 billion. In the fiscal year ended 2026-03-31, FDC reported ₹21.6B in revenue and ₹2.8B in net income.

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally.

Interactive charts & full statements →

FDC Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹21.6B	₹21.0B	₹19.4B	₹17.8B
Gross Profit	₹14.2B	₹13.4B	₹12.5B	₹10.9B
Operating Income (EBIT)	₹2.9B	₹2.7B	₹3.0B	₹2.1B
Net Income	₹2.8B	₹2.7B	₹3.1B	₹1.9B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FDC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹6.7B	₹5.8B	₹4.6B	₹4.7B	₹6.5B	—	—
Gross Profit	₹4.5B	₹3.8B	₹3.1B	₹3.3B	₹4.4B	—	—
Operating Income (EBIT)	₹1.3B	₹920M	₹375M	₹186M	₹1.3B	—	—
Net Income	₹1.3B	₹1.0B	₹283M	₹284M	₹1.2B	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FDC Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹810M)	(₹811M)	(₹2M)	(₹2M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FDC Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹29.2B	₹27.1B	₹24.7B	₹23.4B	—
Total Liabilities	₹4.3B	₹4.3B	₹3.7B	₹3.6B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FDC viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4569 · KYORIN Pharmaceutical Co., Ltd. — JPY 65 billion
SPARC · Sun Pharma Advanced Research Company Limited — ₹63 billion
4886 · ASKA Pharmaceutical Holdings Co.,Ltd. — JPY 62 billion
IOLCP · IOL Chemicals and Pharmaceuticals Limited — ₹60 billion
GUJTHEM · Gujarat Themis Biosyn Limited — ₹56 billion
NOVARTIND · Novartis India Limited — ₹51 billion
ORCHPHARMA · Orchid Pharma Limited — ₹50 billion
4554 · Fuji Pharma Co., Ltd. — JPY 49 billion

← FDBC All “F” companies FDCF →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.